Brief: Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results Cytovance Selected For Cgmp Manufacturing
01/04/2026 14:16
April 1 (Reuters) - Anixa Biosciences Inc ANIX.O: ANIXA BIOSCIENCES ADVANCES BREAST CANCER VACCINE TOWARD PHASE 2 AFTER POSITIVE PHASE 1 RESULTS; CYTOVANCE SELECTED FOR CGMP MANUFACTURING ANIXA BIOSCIENCES INC: PHASE 1 STUDY MET PRIMARY ENDPOINTS, SHOWED SAFETY AND TOLERABILITY AT MAXIMUM TOLERATED DOSE Source text: ID:nPnb4bhJla Further company coverage: ANIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine